NASDAQ:IMV IMV (IMV) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free IMV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.49▼$0.9152-Week Range N/AVolume44,800 shsAverage Volume233,607 shsMarket Capitalization$9.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get IMV alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About IMV Stock (NASDAQ:IMV)IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… IMV Stock News HeadlinesMarch 28, 2024 | finanznachrichten.deCalciMedica, Inc.: CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate UpdatesMarch 27, 2024 | msn.comPhilippines sales up in February 2024March 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 26, 2024 | msn.comAn Electric Toyota Hilux Is Reportedly Coming by 2025March 26, 2024 | msn.comThe New FJ Cruiser Could Use Toyota's $13,000 Truck PlatformMarch 25, 2024 | theguardian.comAsian hornet may have become established in UK, sighting suggestsMarch 22, 2024 | finanznachrichten.deBioVaxys Technology Corp.: BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENTMarch 21, 2024 | finance.yahoo.comBioVaxys Technology Corp. Provides Bi-Weekly MCTO Status UpdateMarch 29, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 13, 2024 | msn.com16 Things We Know About the All-New 2024 Chevelle 70/SSMarch 11, 2024 | msn.comPotential Return of Toyota FJ Cruiser with Utilization of Hilux Champ’s PlatformMarch 8, 2024 | msn.comToyota Mini Fortuner launch compact Fortuner price Scorpio N line mini fortuner featuresMarch 8, 2024 | msn.comVersatile, Vigorous, and Victorious: The Toyota Hilux Champ Dominates the StageMarch 7, 2024 | msn.comToyota FJ to return as a sub-LandCruiser sized SUV – reportMarch 7, 2024 | msn.comRugged New Fortuner-Based Smaller SUV Could Cost Rs 25 lakh?March 5, 2024 | finanznachrichten.deBioVaxys Technology Corp.: BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent ApplicationsMarch 5, 2024 | finance.yahoo.comBioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent ApplicationsFebruary 29, 2024 | uk.finance.yahoo.comQ4 2023 Horizon Technology Finance Corp Earnings CallFebruary 26, 2024 | msn.comRisk profile tool provides clearer insight on hospitalized COVID-19 patients who benefit most from baricitinib treatmentFebruary 23, 2024 | msn.comTrump Rambles His Way Through Incoherent Nashville SpeechFebruary 23, 2024 | msn.comPrivate lander makes first US moon landing in more than 50 yearsFebruary 16, 2024 | msn.comAsk A Doctor: What Problems Can A Hernia Cause?February 13, 2024 | msn.comDon't Fall For These 12 Fried Chicken MythsFebruary 13, 2024 | finanznachrichten.deCalciMedica, Inc.: CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora for the Treatment of Severe Acute Kidney InjuryFebruary 13, 2024 | finance.yahoo.comCalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney InjuryFebruary 12, 2024 | baystreet.caBiovaxys Technology CorpFebruary 12, 2024 | finance.yahoo.comBioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.See More Headlines Receive IMV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMV CUSIPN/A CIK1734768 Webimv-inc.com Phone(902) 492-1819FaxN/AEmployees97Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,990,000.00 Net Margins-11,547.42% Pretax Margin-11,547.42% Return on Equity-12,695.41% Return on Assets-104.84% Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick Ratio2.93 Sales & Book Value Annual Sales$330,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / BookN/AMiscellaneous Outstanding Shares11,712,000Free Float11,673,000Market Cap$9.63 million OptionableOptionable Beta0.95 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesAndrew HallChief Executive Office & DirectorJennifer SchmitkeChief Operating OfficerBrittany DavisonChief Accounting Officer, Director & SVP-financeJeremy R. GraffChief Scientific OfficerStéphane FisetVice President-Clinical ResearchKey CompetitorsMustang BioNASDAQ:MBIOAeterna ZentarisNASDAQ:AEZSGalera TherapeuticsNASDAQ:GRTXHepion PharmaceuticalsNASDAQ:HEPATonix PharmaceuticalsNASDAQ:TNXPView All Competitors IMV Stock Analysis - Frequently Asked Questions Should I buy or sell IMV stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IMV in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IMV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMV, but not buy additional shares or sell existing shares. View IMV analyst ratings or view top-rated stocks. How were IMV's earnings last quarter? IMV Inc. (NASDAQ:IMV) released its quarterly earnings results on Thursday, November, 11th. The company reported ($1.30) EPS for the quarter, meeting analysts' consensus estimates of ($1.30). The business earned $0.04 million during the quarter. IMV had a negative net margin of 11,547.42% and a negative trailing twelve-month return on equity of 12,695.41%. During the same quarter in the prior year, the business earned ($1.00) EPS. When did IMV's stock split? IMV's stock reverse split on the morning of Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. This page (NASDAQ:IMV) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMV Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.